-

Applied BioCode Submits BioCode® Respiratory Pathogen Panel (RPP) with KingFisher™ Nucleic Acid Extraction Claim to the FDA

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode, a leader in innovative molecular diagnostic solutions, announced today the submission of a new nucleic acid extraction claim for the KingFisher™ Flex Nucleic Acid Purification System in combination with the BioCode® Respiratory Pathogen Panel (RPP). This submission is aimed at expanding the use of the BioCode® RPP, enabling laboratories to further streamline workflows while maintaining high-quality, reliable results.

Submitting this claim represents a significant step in our mission to support clinical laboratories with versatile, high-performance molecular testing solutions, said Elisabeth Laderman, CSO.

Share

The new submission supports optimized extraction protocols on the KingFisher™ Flex system, providing laboratories with enhanced flexibility and efficiency for high-throughput respiratory pathogen testing. By pairing the proven capabilities of the BioCode® RPP with the KingFisher™ Flex system, labs can expect faster turnaround times, simplified processes, and consistent performance across multiple targets.

“Submitting this claim represents a significant step in our mission to support clinical laboratories with versatile, high-performance molecular testing solutions,” said Elisabeth Laderman, CSO. “This enhancement reinforces our commitment to enabling accurate and timely respiratory pathogen detection for high-volume testing environments.”

This submission builds on Applied BioCode’s prior FDA clearance of the BioCode® Gastrointestinal Pathogen Panel (GPP) with the KingFisher™ Flex system, demonstrating the company’s continued success in validating flexible, high-throughput extraction solutions across its multiplexed panel portfolio.

Applied BioCode continues to advance molecular diagnostic solutions that meet the evolving needs of clinical laboratories, supporting patient care with accurate, reliable, and actionable results.

About Applied BioCode

Applied BioCode is a leading provider of molecular diagnostic solutions, dedicated to delivering innovative technologies that empower laboratories, improve workflow efficiency, and enhance patient care.

For more information about the new nucleic acid extraction claim for BioCode® RPP or to learn more about Applied BioCode’s innovative diagnostic solutions, please visit https://www.apbiocode.com/products/.

Contacts

Media Contact:
Applied BioCode
Winston Ho
Communications@apbiocode.com

Applied BioCode

TWSE:6598

Release Versions

Contacts

Media Contact:
Applied BioCode
Winston Ho
Communications@apbiocode.com

More News From Applied BioCode

Applied BioCode Announces New Nucleic Acid Extraction Claim for KingFisher™ Flex Nucleic Acid Purification System with BioCode® Gastrointestinal Pathogen Panel (GPP)

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode, a leader in molecular diagnostics panel testing, is excited to announce a significant enhancement to its BioCode® Gastrointestinal Pathogen Panel (GPP) with the addition of nucleic acid extraction claim for the widely adopted ThermoFisher Scientific KingFisher™ Flex platform. This expansion enables greater workflow flexibility and optimized sample processing capabilities for clinical laboratories running the BioCode® GPP. This enhancem...

Applied BioCode Announces the Launch of the STI + Resistance Panel Assay for Research Use Only

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode announces the launch of the BioCode® STI + Resistance Panel (RUO)....

Applied BioCode Announces Retirement of CEO Chris Bernard

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode announced today the retirement of Chris Bernard as Chief Executive Officer. Chris Bernard has served as CEO for the past two years and has been instrumental in guiding the company through a period of growth and innovation. During his tenure, Chris played a pivotal role in advancing Applied BioCode’s strategic initiatives and driving the company’s commitment to delivering cutting-edge solutions to the molecular diagnostics market. His le...
Back to Newsroom